Neoadjuvant transcatheter arterial chemoembolization and systemic chemotherapy for the treatment of undifferentiated embryonal sarcoma of the liver in children

Table 1 Clinicpathological data, treatment, follow-up and outcome of 6 patients with undifferentiated embryonal sarcoma of the liver

No.	Age	Sex	Tumor size on admission (mm)	Symptoms	Metastasis	Treatment	Tumor shrunk after NAT	Response after one cycle of NAT	Outcome (follow-up years)
1	10 years old	F	120	Abdominal mass	None	Neoadjuvant therapy/surgery/chemotherapy	33%	SD	Alive and event-free at 15
2	3 years and 7 months old	M	86	Abdominal pain	Lung metastases	Neoadjuvant therapy/surgery/chemotherapy	68.70%	PR	Alive and event-free at 11
3	7 years old	F	96	Abdominal pain	None	Neoadjuvant therapy/surgery/chemotherapy	31%	PR	Alive and event-free at 10
4	11 years and 8 months old	M	137	Abdominal pain	None	Two cycles of neoadjuvant therapy/surgery/chemotherapy	18.2% after one cycle; 43.2% after two cycles	SD	Alive and event-free at 7
5	6 years and 8 months old	M	136	Abdominal mass	Retroperitoneal lymph node metastasis	Two cycles of neoadjuvant therapy/surgery/chemotherapy	17.6% after one cycle; 47.3% after two cycles	SD	Alive and event-free at 3
6	5 years and 3 months old	M	148	Jaundice	None	Neoadjuvant therapy/surgery/chemotherapy	48.80%	PR	Alive and event-free at 2

PR: Partial response; SD: Stable disease; NAT: Neoadjuvant therapy.